Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8YS6

Helicobacter pylori OorDABC in complex with Napabucasin

これはPDB形式変換不可エントリーです。
8YS6 の概要
エントリーDOI10.2210/pdb8ys6/pdb
EMDBエントリー39557
分子名称2-oxoglutarate:acceptor oxidoreductase, 2-oxoglutarate synthase subunit alpha, 2-oxoglutarate ferredoxin oxidoreductase subunit beta, ... (8 entities in total)
機能のキーワードoxoglutarate oxidoreductase, electron transport, tricarboxylic acid cycle, napabucasin, oxidoreductase
由来する生物種Helicobacter pylori
詳細
タンパク質・核酸の鎖数8
化学式量合計213026.86
構造登録者
Lan, W.,Gao, Y.,Bi, H. (登録日: 2024-03-22, 公開日: 2025-07-02, 最終更新日: 2026-01-21)
主引用文献Hang, X.,Lan, W.,Yanqiang, H.,Huang, H.,Zhang, M.,Zeng, L.,Shi, T.,Bai, Y.,Yang, Z.,Hu, S.,Wang, J.,Dong, L.,Tong, Q.,Jia, J.,Bi, S.,Xia, Q.,Gao, Y.,Bi, H.
2-oxoglutarate:acceptor oxidoreductase-catalyzed redox cycling effectively targets coccoid forms of Helicobacter pylori.
Nat Commun, 16:6965-6965, 2025
Cited by
PubMed Abstract: Helicobacter pylori, a globally significant pathogen, plays a central etiological role in diverse gastric pathologies ranging from chronic gastritis and peptic ulcers to gastric adenocarcinoma. Although conventional antibiotics effectively inhibit or kill growing helical H. pylori, metabolically dormant coccoid forms of H. pylori exhibit considerable tolerance, posing a persistent and clinically significant challenge. Here, we report napabucasin (2-acetylfuro-1,4-naphthoquinone) as a redox-cycling antibiotic with potent bactericidal activity against both drug-resistant helical and coccoid forms of H. pylori. Notably, napabucasin does not induce acquired resistance in vitro and demonstrates superior efficacy compared to standard triple therapy in murine infection models. Mechanistic studies reveal that napabucasin acts through 2-oxoglutarate:acceptor oxidoreductase (OOR)-catalyzed futile redox cycling, generating bactericidal levels of reactive oxygen species (ROS). Compared to menaquinone 6, a proposed physiological electron acceptor, napabucasin exhibits enhanced oxidative capacity. Structural, biochemical, and microbiological analyses identify Leu44 and Lys46 within the OorD subunit as critical residues for napabucasin recognition and catalysis. These findings establish OOR-mediated redox cycling as a robust antimicrobial strategy that sustains endogenous ROS production to combat refractory H. pylori infections.
PubMed: 40730563
DOI: 10.1038/s41467-025-62477-4
主引用文献が同じPDBエントリー
実験手法
ELECTRON MICROSCOPY (3.03 Å)
構造検証レポート
Validation report summary of 8ys6
検証レポート(詳細版)ダウンロードをダウンロード

252456

件を2026-04-22に公開中

PDB statisticsPDBj update infoContact PDBjnumon